Better Health for All

CollPlant's core business is dedicated to developing regenerative medicine products, including rhCollagen for tissue regeneration, 3D bioprinted breast implants, dermal fillers, and wound healing solutions, all aimed at improving health outcomes and offering safer alternatives. A study on VergenixFG showed a 94% median wound area reduction within 4 weeks and 50% pain reduction in all patients.

Pre-clinical and 6-month studies for regenerative breast implants reported no adverse reactions or complications. The company's rhCollagen is designed to eliminate allergic or immune responses, and products undergo toxic-screening. CollPlant uses Computational Modeling and Simulation to accelerate safer solutions and minimize animal testing. The company reported zero complaints concerning breaches of customer data in 2023. CollPlant joined the UN Global Compact in September 2023, supporting SDG 3.8 for universal health coverage. However, the company's response to the 'Iron Swords' War involved supporting the Israel Defense Forces and people of Israel, which is a localized response to a conflict rather than a global health crisis. The company's 2024 revenue decreased to $515,000 from $10.96 million in 2023, primarily due to a milestone payment in 2023. The company's sustainability report mentions a commitment to transparency and accountability but also notes a fraud and embezzlement risk survey in May 2024 with findings and recommendations currently being addressed. CollPlant offers opportunities for personal and professional growth and development through courses, training, and personalized career paths for its employees, with 3 average hours of training per employee in 2023.

Fair Money & Economic Opportunity

CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine company, not a financial institution. The company does not offer lending, insurance, or deposit services to consumers, nor does it manage customer financial data or provide debt products.

Therefore, all KPIs related to financial services, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives (financial), data accessibility (financial), fair lending compliance, wealth building outcomes (financial), profit reinvestment (community finance), financial literacy initiatives, debt burden ratio, geographic inclusion (banking deserts), and product simplicity (financial products), are not applicable to its core business model. While the company's operations may create economic opportunities for farmers, this does not directly align with the specific metrics of the 'wealth_building_outcome' KPI, which focuses on financial service users' credit scores, savings, and homeownership.

Fair Pay & Worker Respect

The company's Total Recordable Incident Rate (TRIR) was 3.44 in 2023.

Employee reviews on Glassdoor show an overall rating of 2.90 out of 5, with 48% of employees recommending the company to a friend. The voluntary employee turnover rate was 26% in 2023. The company reported zero incidents of non-compliance in 2023.

Fair Trade & Ethical Sourcing

CollPlant directed 78% of its procurement budget to local suppliers in 2023.

This figure has decreased from 89% in 2021 and 88% in 2022.

Honest & Fair Business

Based on the provided information, there is insufficient evidence to assess CollPlant Biotechnologies' performance regarding honest and fair business practices. The provided document is a code of conduct, which outlines expected behavior but does not provide quantitative data or evidence of actual practices.

Without specific data on regulatory fines, transparency index scores, whistleblower policy effectiveness, or other relevant metrics, a neutral score is assigned. The company's business model has medium materiality to this value, as ethical conduct is important for regulatory compliance and maintaining trust, but not inherently central to their product offerings. More information is needed to provide an accurate assessment.

Kind to Animals

CollPlant's core product, recombinant human collagen (rhCollagen), is plant-derived, eliminating the need for animal-derived collagen and associated ethical concerns.

This effectively means 100% of this key animal input has been replaced with an ethical alternative. The company's Collink.3D bioinks are animal-free and designed for use in non-animal testing applications like tissue-on-a-chip or organ-on-a-chip systems. CollPlant minimizes animal testing in preclinical trials using simulation techniques such as Finite Element Analysis (FEA) and Computational Modeling and Simulation (CM&S), and adheres to the 3 Rs (Replacement, Reduction, and Refinement). The company's products are designed to be animal-free, and it develops alternatives to animal testing in response to FDA initiatives, indicating an absolute global ban on animal testing. CollPlant's R&D is focused on 3D bioprinting bioinks and regenerative breast implants, which are animal-free technologies. The company's plant-based rhCollagen production reduces land usage compared to animal-derived collagen, and it uses conservation tillage. CollPlant supports the United Nations’ Sustainable Development Goals (SDGs) and is an official signatory of the UN Global Compact since August 2023.

No War, No Weapons

CollPlant Biotechnologies Ltd. operates in the regenerative and aesthetic medicine sector, focusing on rhCollagen technology and 3D bioprinting for civilian medical applications.

The company does not report any revenue from arms or defense contracts, nor does it develop or sell dual-use technologies with military applications. There is no evidence of sales to embargoed or sanctioned regimes. In July 2024, the company announced it joined the United Nations Global Compact, covering the fiscal year 2023, which indicates alignment with UN Guiding Principles on Business and Human Rights. The company's business model does not involve weapons, and there is no evidence of exposure to controversial or banned weapons, or the need for ethical red lines related to weapons.

Planet-Friendly Business

CollPlant Biotechnologies released its inaugural ESG and Sustainability Report for 2023, outlining a strategy anchored in three pillars: Impact on the Planet, Impact on People, and Impact on Business Conduct.

The company is a signatory of the UN Global Compact, committing to environmental responsibility. Its plant-based collagen production approach is highlighted for reduced land usage, no-till farming, and minimized chemical applications. However, the provided articles do not contain specific quantitative data for any of the environmental performance metrics required by the rubric.

Respect for Cultures & Communities

CollPlant Biotechnologies reported zero cultural appropriation incidents as of 2023.

The company states that 100% of its employees are local. As of 2023, 78% of the procurement budget was spent on local suppliers in Israel. All employees receive training on the Code of Business Conduct and Ethics.

Safe & Smart Tech

In 2023, the company reported 0 complaints concerning breaches of customer data.

The company has an ISO 13485-certified quality management system (QMS) and a QSD 20000 Safety Procedure. However, the QMS and Safety Procedure are general quality and safety management systems, not specifically privacy or security certifications. The company reported 0 incidents of non-compliance in 2023, but the rubric for regulatory compliance requires more specific evidence of a comprehensive program beyond just no reported incidents.

Zero Waste & Sustainable Products

CollPlant Biotechnologies' sustainability reports highlight a plant-based approach to rhCollagen production, aiming to reduce environmental impact through methods like reduced land usage, no-till farming, and minimizing chemical applications.

The company also states its support for UN Sustainable Development Goals, including SDG 12 (Responsible Consumption and Production), and is a signatory to the UN Global Compact. However, the provided articles do not contain any specific quantitative data or measurable outcomes related to waste management, product recyclability, packaging sustainability, recycled content, waste reduction targets, or other relevant metrics for the 'Zero Waste & Sustainable Products' value. Therefore, no KPIs can be scored based on the available evidence.